1. |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229-263.
|
2. |
姚一菲, 孙可欣, 郑荣寿. 《2022全球癌症统计报告》解读: 中国与全球对比. 中国普外基础与临床杂志, 2024, 31(7): 769-780.
|
3. |
Deng Y, Zhao P, Zhou L, et al. Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study. J Hematol Oncol, 2020, 13(1): 98.
|
4. |
陆如山, 陈新华. 世界卫生组织十分重视全球控烟工作. 中国健康教育, 1995, (6): 23-25.
|
5. |
Yang JJ, Yu D, Wen W, et al. Tobacco smoking and mortality in Asia. JAMA Netw Open, 2019, 2(3): e191474.
|
6. |
赫捷, 李霓, 陈万青, 等. 中国肺癌筛查与早诊早治指南(2021, 北京). 中国肿瘤, 2021, 30(2): 81-111.
|
7. |
Huang S, Tang O, Zheng X, et al. Effectiveness of smoking cessation on the high-risk population of lung cancer with early screening: a systematic review and meta-analysis of randomized controlled trials until January 2022. Arch Public Health, 2023, 81(1): 101.
|
8. |
Liu Y, Ni R, Zhang H, et al. Identification of feature genes for smoking-related lung adenocarcinoma based on gene expression profile data. Onco Targets Ther, 2016, 9: 7397-7407.
|
9. |
Wang J, Guo C, Wang J, et al. Tumor mutation signature reveals the risk factors of lung adenocarcinoma with EGFR or KRAS mutation. Cancer Control, 2025, 32: 10732748241307363.
|
10. |
Zhang J, Zhang Y, Lei Y, et al. Elevated serum direct bilirubin and smoking status are prognostic factors for EGFR-mutated non-small cell lung cancer patients receiving tyrosine kinase inhibitor therapy. Cancers (Basel), 2024, 16(23): 3982.
|
11. |
钟文昭, 李巍, 黄劭洪, 等. 性别、吸烟状态及病理类型对肺癌患者化学治疗和手术预后的影响. 新医学, 2015, 46(7): 433-438.
|
12. |
Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res, 2005, 11(14): 5084-5089.
|
13. |
王辰, 肖丹, 池慧. 《中国吸烟危害健康报告2020》概要. 中国循环杂志, 2021, 36(10): 937-952.
|
14. |
任泽平. 中国老龄化报告. 发展研究, 2023, 40(2): 22-30.
|
15. |
卫生健康委, 发展改革委, 教育部, 等. 关于印发健康中国行动—癌症防治实施方案(2019-2022年)的通知. 2019.
|
16. |
董懂, 张亚杰, 李鹤成. 2024年第2版《NCCN肿瘤临床实践指南—肺癌筛查》更新解读. 中国胸心血管外科临床杂志, 2024, 31(9): 1253-1257.
|
17. |
NCCN. NCCN clinical practice guidelines in oncology: non-small cell lung cancer version 5. 2024.
|
18. |
徐明翠, 王剑, 阳韬. 晚期非小细胞肺癌靶向治疗进展. 临床肺科杂志, 2023, 28(1): 108-116.
|
19. |
李西岳, 王洵, 朱雪. 人表皮生长因子受体2阳性非小细胞肺癌靶向治疗药物临床研究进展. 中国新药杂志, 2024, 33(9): 895-903.
|
20. |
廖光英, 张滨, 陈小丹. 基于2020年中国家庭追踪调查的我国15-64岁居民吸烟现状及影响因素. 预防医学论坛, 2023, 29(1): 15-18.
|
21. |
Olivieri M, Murgia N, Carsin AE, et al. Effects of smoking bans on passive smoking exposure at work and at home: the European community respiratory health survey. Indoor Air, 2019, 29(4): 670-679.
|
22. |
International Early Lung Cancer Action Program Investigators, Henschke CI, Yip R, et al. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA, 2006, 296(2): 180-184.
|
23. |
Kawai H, Ishii A, Washiya K, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res, 2005, 11(14): 5084-5089.
|
24. |
高冬青, 王家林. 肺癌危险因素研究现状. 中华肿瘤防治杂志, 2019, 26(21): 1657-1662.
|
25. |
梁锌, 刘梦雯, 张丽, 等. 全球部分地区肺癌发病趋势及年龄变化情况分析. 中国肿瘤, 2022, 31(9): 683-692.
|
26. |
胡志强, 游伟程, 潘凯枫, 等. 中、美两国癌症流行特征分析—《2023美国癌症统计报告》解读. 科技导报, 2023, 41(18): 18-28.
|
27. |
孙燕. 肿瘤内科治疗的回顾和展望. 国外医学(肿瘤学分册), 2000, (1): 5-11.
|
28. |
许靖, 余欣, 马洪涛, 等. 2006-2020年中国肺癌死亡趋势分析—基于年龄-时期-队列模型. 肿瘤防治研究, 2023, 50(8): 788-793.
|
29. |
马运, 袁浩冉, 胡昊, 等. 1990-2019年中国归因于烟草的肺癌疾病负担变化趋势分析. 现代预防医学, 2024, 51(8): 1345-1351.
|
30. |
辛雯艳, 郭晓莉, 何小双, 等. 1990-2019年我国居民肺癌死亡水平与疾病负担趋势预测研究. 中华肿瘤防治杂志, 2024, 31(2): 65-73.
|
31. |
薛雯, 钟理, 周敬华. 吸烟致肺癌机制及遗传易感因素研究进展. 中国公共卫生, 2011, 27(8): 958-960.
|
32. |
Nagah A, Amer A. Different mechanisms of cigarette smoking-induced lung cancer. Acta Biotheor, 2021, 69(1): 37-52.
|